

Alternatives to Animal Testing and EXperimentation

Instructions to Authors

1. Aims and Scope

Alternatives to Animal Testing and EXperimentation (AATEX) is an official peer-reviewed and fully open-access journal of the Japanese Society for Alternatives to Animal Experimentations. The journal publishes original articles, brief communications, reviews, and letters to the editor. The aim of the publication of AATEX is to gather and disseminate scientific and technological information on the development and implementation of alternatives to the use of animals for scientific purposes based on the Three Rs. The scope of AATEX covers broad aspects of Three Rs. (1) Reduction, which refers to obtaining comparable levels of information from fewer animals; (2) Refinement, which refers to methods for alleviating potential pain, suffering, or distress of animals used in experiments; (3) Replacement, which refers to the use of non-animal methods whenever possible. We are respectful to the contributors for supporting the publication of the journal, which will advance the development of science and technology for alternative to animal experiments. All articles receive a full and extensive peer review by recognized experts from the subject of research field. The journal is published twice a year (September and December). AATEX requires that all manuscripts be prepared in accordance with the [“Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly work in Medical Journals”](#) as published by the International Committee of Medical Journal Editors (ICMJE).

2. Article Types

AATEX publishes a variety of different article types. Once you have determined the correct Article Type, it is imperative that you read the Manuscript Preparation guidelines before you submit your manuscript:

1. Original Articles
Original Articles are scientific reports with the development of alternatives to laboratory animals
2. Brief Communications
Brief Communications may report on important new findings warranting expeditious publication.
3. Review
Review Articles are summaries of relate topics of current significance or themes with information accessible to the general members.
4. Letter to the Editor
Letters to the Editor are brief, constructive commentaries that can be submitted in response to a recently published article in the journal.

3. Manuscript Preparation

Information provided here on manuscript preparation and formatting is based, in part, on the [“Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals”](#) as published by the ICMJE. For any information that is not mentioned in this guideline, authors should refer to the [ICMJE Recommendations](#).

Authors wishing to include figures, tables, or text passages that have already been published elsewhere are required to obtain permission from the copyright owner(s) for publication. Authors must submit permissions letters from the copyright owner(s) when submitting the manuscript. A full credit line should be added to the copyrighted material in the manuscript.

If authors are non-native speakers of English, the manuscript must be edited by a native English speaker prior to submission, preferably one with a specialized knowledge of medical editing.

Manuscripts that do not follow the instructions below WILL BE RETURNED to the corresponding author for technical revision before undergoing peer review.

Required Forms:

- Submission Form, Please contact the Chief Editor. E-mail: komizu@bio.sojo-u.ac.jp
- Copyright Transfer;

3.1 *General Formatting*

All articles should be written in English using size 12, "Times New Roman" font type and correctly formatted according to the guidelines outlined below. All text should be double-spaced. Line numbers and page numbers on each page are required to make it easier for reviewers to provide comments.

The organization of the manuscript should be in the following order:

- Title Page
- Abstract
- Key Words
- Main Text
- References
- Figure Legends
- Figures
- Tables and footnotes
- Supplemental Files (e.g., pptx files and pdf files, if applicable)

3.1.1 *Title Page*

The title page should be prepared separately from the main document and must include the following information:

- Article type
- Title of the manuscript (No abbreviations except for gene names or in common use)
- Running title (no more than 45 letters and spaces)
- Full names of all authors
- Institutional affiliations of all authors, indicated by numbers (not symbols), including city and country
Corresponding author's name, address, telephone number and e-mail address
- Word count (for the main text only)
- Conflicts of interest
- Sources of financial support that require acknowledgment
- Type of contribution of the authors. Please visit the [ICMJE website](#) for more information on authorship.
- Approval code issued by the institutional review board (IRB) and the name of the institution(s) that granted the approval.
- Acknowledgements (other than sources of financial support)
- A statement that appropriate informed consent was obtained. If the consent from the participants was waived for your study, the reason(s) must be stated explicitly.

3.1.2 *Main Document*

Abstract and Key Words

Manuscript should include an abstract of no more than 200 words that includes the following headings, depending on the article type:

- Review Article: Unstructured Abstract
- Original Article: Structured Abstract (Background, Methods, Results, Conclusions)
- Brief Communication: Unstructured Abstract
- Letter to the Editor: Abstract is not necessary.

The Abstract, regardless of the Article Type, should contain 3 to 5 key words. The abstract must be precise, clear and fully comprehensible on its own. The Abstract of clinical trials must include the registration number and name of the registration database. See further details on clinical trials section below.

Main Text

The main text should be prepared in MS Word (.doc or .docx). For each Article Type, authors must organize and order their content using the following formats:

Original Article:

Headings: Introduction, Materials and Methods, Results, Discussion

Word Limit: 3,500 words

Number of Tables: No more than 5

Number of Figures: No more than 6

Number of References: No more than 50

Brief Communication:

Word Limit: 1,500 words

Number of Tables and Figures: No more than 5

Number of References: No more than 20

Review:

Word Limit: 4,000 words

Number of Tables: No more than 8

Number of Figures: No more than 10

Number of References: No more than 80

Letter to the Editor:

Word Limit: 400 words

Number of Tables and Figures: No more than 1

Number of References: No more than 5

Article Type	Abstract		Main Text		Tables/ Figures	References
	Style	Words	Headings	Words		
Original Article	Structured	250	Introduction, Materials and Methods, Results, Discussion,	3,500	5/6	50
Brief Communication	Unstructured	250	-	1500	5	20
Review Article	Unstructured	250	-	4,000	8/10	80
Letter to the Editor	Not necessary	-	-	400	1	5

3.2 References

- The authors are responsible for the accuracy of their references.
- Including AI-generated material as the primary source in the reference is not allowed.
- The References section should follow immediately after the conclusion of the main text under the heading "References".
- References should be prepared according to the Vancouver style, based on the latest edition of [Citing Medicine](#) published by the U.S. National Library of Medicine.

- For reference styles pertaining to other media formats or further details not shown in the following examples, please refer to above-mentioned guide.
- Authors must cite references in the text in the order of their appearance, using superscript numbers. e.g., superscript [1]
- If there are more than three authors, name only the first three authors and then use “et al.”
- Japanese references must be translated into English in order to include in the reference section.

Examples:

Journal and Periodicals:

1. Watanabe M, Suzuki K, Kodama S, et al. Normal human cells at confluence get heat resistance by accumulation of hsp72 in nucleus. *Carcinogenesis*. 1995;16:2373–2380.

Books:

2. Watanabe M, Suzuki K, Kato T. LET dependency of mutation induction at HPRT locus in human cells irradiated with heavy ions. In: Chadwick KH, Thaker J, editors. *Molecular Mechanisms in Radiation Mutagenesis and Carcinogenesis*. Brussels: European Commission; 1994. p.177–181.

3.3 Units of Measurement

Measurements of length, height, weight, and volume should be reported in metric units (meter, kilogram, or liter) or their decimal multiples. Temperatures should be in degrees Celsius. Blood pressures should be in millimeters of mercury. All measurements should follow the International System of Units (SI). Except for °C and %, one space must be inserted between each number and unit.

Use a capital letter "L" for liter in the units of measurements in the Text, Figures, and Tables (e.g., g/dL, mg/dL, IU/L, and mEq/L).

3.4 Abbreviations

Do not include the abbreviations in the title or abstract except for gene name. Define all abbreviations at their first appearance in the main text and in each Table and Figure and use the abbreviations consistently thereafter. SI units are preferred.

3.5 Names of Drugs, Devices, and Other Products

Do not use the specific brand names of drugs, devices, and other products and services, unless it is essential to the discussion. Otherwise, please use descriptive name.

3.6 Figures and Tables

Figures and Tables should be numbered consecutively with Arabic numerals (e.g. Fig. 1, Fig. 2, Table 1, Table 2), and must be cited in the text in bold in the order they are cited.

If any copyrighted or previously published material, edited or otherwise, are used in the manuscript, it is the author’s responsibility to obtain the permission from the copyright owner(s) prior to making a submission. Also, the authors must cite the source and indicate the permission to use such materials in the corresponding Figure or Table caption, as required by the copyright owner(s). Authors must submit permissions letters from the copyright owner(s) when submitting the manuscript.

3.6.1 Figures

Plan all figures to fit the proportions of the printed page (25.5 cm x 17 cm, B5). Line drawing should be carefully drawn in black ink on white paper or submitted as glossy prints. Each figure should be identified on the back with the author’s name and the figure number. Magnification should be indicated by scale bars. Figures supplied within the main manuscript Word document or previously copy-and-pasted in PowerPoint are not acceptable. This is due to their low resolution. They will not re-produce in print or online clearly.

3.6.2 Figure Legends

Legends must be prepared for all Figures presented in the manuscript and should be understandable without reference to the text. Authors must list Figure Legends on a separate page after the References section.

3.6.3 Tables and Footnotes

Tables should be typed-spaced on separate pages and be configured in a horizontal layout only. Tables are required to be in MS Word (.doc/.docx) or PowerPoint (.ppt/.pptx). Do not use MS Excel or comparable spreadsheet software. The Table captions should be understandable without reference to the text. Column headings should be kept as brief as possible and indicate units. Footnotes should be labeled a), b), c), etc. and typed on the same page as the table they refer to.

3.6.4 Supplementary Materials

AATEX accepts supplementary materials that may contain additional figures or tables. The authors should submit the supplementary materials as “Supplemental File” during the manuscript submission process. Each file must be within 50 MB. Refer to the supplementary materials starting with S1, S2 (e.g. Fig. S1, Table S1) in the manuscript's main text. Supplementary materials are published exactly as they are received and not edited by the journal. All supplementary materials will be published alongside the article on the journal website.

4. Clinical Trials

In accordance with [ICMJE's policy](#) on trial registration, all clinical trials must be registered with a public trials registry before the time of first patient enrollment. ICMJE defines clinical trials as any research project that prospectively assigns people or a group of people to an intervention, with or without concurrent comparison or control groups, to study the cause-and-effect relationship between a health-related intervention and a health outcome. Health-related interventions include, but are not limited to, those used to modify a biomedical or health-related outcome; examples include drugs, surgical procedures, devices, behavioral treatments, educational programs, dietary interventions, quality improvement interventions, and process-of-care changes.

AATEX requires all clinical trials to be registered with databases that are accessible to the public at no charge, open to all prospective registrants, managed by a not-for-profit organization, have a mechanism to ensure the validity of the registration data, and are electronically searchable.

Submitted manuscripts must include the unique registration number in the abstract as evidence of registration. The name of the registration database must also be provided. For details regarding the required minimal registration data set, please go to the ICMJE site at <http://www.icmje.org/recommendations/browse/publishing-and-editorial-issues/clinical-trial-registration.html>

The journal accepts registration from the following list of registries as well as others listed at ICMJE site:

- Clinical Trials (<https://www.clinicaltrials.gov/>)
- Australian New Zealand Clinical Trials Registry (<http://anzctr.org.au>)
- ISRCTN Register (<http://isrctn.org>)
- UMIN Clinical Trials Registry (<https://www.umin.ac.jp/ctr/>)
- EudraCT (<https://eudract.ema.europa.eu/>)

In reporting randomized clinical trials, authors must comply with published CONSORT guidelines (<http://www.consort-statement.org/>). The recommended checklist must be completed and provided to the journal at the time of manuscript submission. The recommended trial flow diagram should be presented as “Supplementary File”.

5. Reporting Guidelines

Various reporting guidelines have been developed for different study designs. Authors are encouraged to follow published standard reporting guidelines for the study discipline.

- CONSORT for randomized clinical trials (<http://www.consort-statement.org/>)
- CARE for case reports (<http://care-statement.org/>)
- STROBE for observational studies (<http://strobe-statement.org/>)
- PRISMA for systematic reviews and meta-analyses (<http://prisma-statement.org/>)
- STARD for studies of diagnostic accuracy (<http://www.equator-network.org/reporting-guidelines/stard/>)
- SAGER for reporting of sex and gender information (<https://www.equator-network.org/reporting-guidelines/sager-guidelines/>)
- ARRIVR for animal researches (<https://arriveguidelines.org/arrive-guidelines>)

Please access <https://www.equator-network.org> to find the guideline that is appropriate for your study.

It is extremely important that when you complete any Reporting Guideline checklist that you consider amending your manuscript to ensure your article addresses all relevant reporting criteria issues delineated in the appropriate reporting checklist. The purpose of a reporting guideline is to guide you in improving the reporting standard of your manuscript. The objective is not to solely complete the reporting checklist, but to use the checklist itself in the writing of your manuscript. Taking the time to ensure your manuscript meets these basic reporting needs will greatly improve your manuscript, while also potentially enhancing its chances for eventual publication.

6. Data Sharing

AATEX encourages the authors of manuscript which includes clinical trials to share their de-identified research data including, but not limited to raw data, processed data, software, algorithms, protocols, methods, materials, study protocol, statistical analysis plan, informed consent form, clinical study report, analytic code.

As required by ICMJE, all manuscripts that report the results of clinical trial must include a data sharing statement with a link to the trial registration. The statement should include the following information:

- Available types of data,
- Available documents (study protocol, statistical analysis plan, informed consent form, clinical study report, or analytic code)
- Available dates
- With whom the data are available.
- Types of analyses the authors are willing to share the data
- Method of requesting the data.

The statement is published alongside their paper.

7. Manuscript Submission

Manuscripts may be sent to:

Yuji Komizu, Editor-in-chief of AATEX, Sojo University
 4-22-1, Ikeda, Nishi-ku, Kumamoto 860-0082, JAPAN
 (TEL +81-96-326-3804 FAX +81-96-323-1331), E-mail: komizu@bio.sojo-u.ac.jp

If you have any questions, please contact the Editor-in-Chief.
komizu@bio.sojo-u.ac.jp

The total size of the attached files should not exceed 20 MB. If the total size of your files exceed 20 MB, please upload them to a secure cloud storage service and share a download link via e-mail. Please make sure to set appropriate access restrictions (e.g., password protection or link expiration). The Editorial Office cannot be held responsible for any disadvantages, including information leakage or data loss, resulting from the use of any file transfer or cloud storage service.

Notification of manuscript submission will be sent by e-mail to all authors listed in the manuscript.

8. Peer Review Process

Articles submitted to AATEX are subject to a single-anonymized peer review process. This means the identities of the peer reviewers remain anonymous but the authors' identities are known to the reviewers. Peer review is a critically important process of evaluation for any manuscript submitted to AATEX. Every article dispatched for full peer review will receive a comprehensive, fair, and unbiased critical assessment.

All submitted manuscripts will be reviewed, initially, by the editors of AATEX to evaluate eligibility for publication. The editors will assess the importance and originality of the research, suitability and interest to the readership of the journal, and the quality of the manuscript. Any manuscripts that satisfy our screening criteria will generally be sent to two experts in the field of the study for peer review. The editors of AATEX will review the peer review comments and make all decisions on the manuscript publication, which include acceptance, major or minor revisions, and rejection.

AATEX adheres to [Committee on Publication Ethics' Ethical Guidelines for Peer Reviewers](#). Reviewers are not allowed to contact the authors directly before, during, or after the peer review process to discuss any information that is presented in the manuscript. Reviewers must keep the manuscripts and information obtained strictly confidential and must not publicly discuss or disclose the contents and any other information contained within the manuscript to a third party. The guidelines for the reviewers are available [here](#).

The decision letters along with the comments by the editors and reviewers will be sent to the corresponding author via e-mail.

8.1 Revised Manuscript

It is expected that any manuscripts receiving a revision decision will be fully amended according to the comments of both the reviewers and the editors. Authors must also include a detailed point-by-point response letter. Authors should submit the revised manuscript within 3 months from the date of prior decision. Revisions must be approved by all authors prior to submission of the revised manuscript.

8.2 Editors and Journal Staff as Authors

Manuscripts submitted by editors, Editorial Board members, or journal staff will follow the same process as outlined above. However, they are excluded from any editorial decision process of their own manuscript and have neither access to that manuscript nor any information about the review process other than what is provided in the editor's decision letter. The manuscript submitted by editors, Editorial Board, and journal staff of AATEX should include a statement that declares their personal conflict of interest with the journal.

9. Editorial Policy and Publication Ethics

9.1 Overview

AATEX observes the highest standards in journal publication. The journal supports and adheres to the guidelines and best practices including [Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals](#) by the [International Committee of Medical Journals Editors](#) (ICMJE) and the [Principles of Transparency and Best Practice in Scholarly Publishing](#) (a joint statement by the [Committee on Publication Ethics](#) (COPE), the [Directory of Open Access Journals](#) (DOAJ), the [World Association for Medical Editors](#) (WAME) and the [Open Access Scholarly Publishers Association](#) (OASPA); (<https://doaj.org/apply/transparency/>)).

9.2 Authorship/Contributorship

All authors listed in the manuscript must meet the following four contribution criteria as defined by the ICMJE in their [Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals](#).

- 1) Substantial contributions to the conception or design of the research or the acquisition and analysis of data; and
- 2) Drafting the work or reviewing it critically for important intellectual content; and
- 3) Final approval of the version to be published; and
- 4) Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Contributors who do not meet all four criteria above should not be listed as authors. Guest or honorary authorship is strictly prohibited.

The corresponding author must ensure that a manuscript is read and approved by ALL authors prior to submission.

Those who do not qualify for authorship may be acknowledged individually or together as a group under a single heading within the “Acknowledgements” on the title page. Examples of activities that do not qualify a contributor for authorship are: acquisition of funding; general supervision of a research group; general administrative support and writing assistance; technical editing; language editing, and proofreading.

Authors should discuss, determine and (if they exist) settle any disagreements about the order of authorship before submitting their manuscript. Final author order must be established by the end of the revision phase of the peer review process. Any authorship changes such as order, addition, and deletion of authors between the initial manuscript submission and the final decision should be discussed and approved by all authors.

Adding, deleting, or changing the author names and their order is not permitted after the acceptance of the manuscript for publication.

9.3 Use of Artificial Intelligence (AI)-Assisted Tools/Technologies

In consonance with the [COPE’s position statement](#), [WAME’s recommendations](#), and [ICMJE’s Recommendation](#), AATEX does not allow artificial intelligence (AI)-assisted tools/technologies such as Large Language Models (LLMs), chatbots, or image creators to be listed as author or co-author. As described in the ICMJE, those tools cannot be responsible for the accuracy, integrity, and originality of the work, thus they do not meet the ICMJE’s criteria for authorship listed above. The authors (humans) are fully responsible for any materials of the submitted work, including the use of AI-assisted tools or technologies. AI should not be cited as an author. Authors (humans) are also responsible for plagiarism including in text and AI-produced images. Authors must disclose, upon submission and in the Materials and Methods (or similar section), any use of AI-assisted tools or technologies in the writing of a manuscript, production of images or graphical elements of the paper, or in the collection and analysis of data.

9.4 Exclusive Submission

Articles that have been previously published or are being considered for publication in another journal in any language will not be accepted. Submission of a manuscript implies that: the work described has not been previously published; it is not under consideration for publication elsewhere; its publication has been approved by all co-authors. The editors make all decisions on the acceptance of the peer-reviewed manuscripts.

9.5 Confidentiality

All manuscript details, author information, reviewer identities, comments to the editors and the authors, and the content of the decision letter are considered privileged information and will never be disclosed to third parties.

9.6 Redundant or Duplicate Publication

Articles that are being considered for publication in another journal including advanced publications such as “in-press” or “E-pub ahead of print” articles in any language might be regarded as redundant or duplicate publication.

The author should notify the editor formally about all submission and the previous reports that could be regarded as redundant or duplicate publication of the same or similar work. Any such material must be referred to and referenced in the new work. Copies of such work should be included with the submission. Abstracts or posters presented at scientific meetings are not considered previously published work. For studies that have been presented at a scientific meeting, “Acknowledgements” should include a sentence, such as "A part of this study has been presented at the XXth Annual Meeting of XXXXX (Month Year, City)".

Editorial actions should be expected if redundant or duplicate publication is attempted or occurs without such notification. Editorial actions may include: immediate rejection of the submitted manuscript; retraction of published work; published notice of violation, and revocation of publishing privileges.

For acceptable secondary publication AATEX accepts secondary publications of only those that meet the criteria and conditions described in the ICMJE Recommendations.

9.7 Conflicts of Interest and Sources of Funding

According to the ICMJE Recommendations, a conflict of interest (COI) exists “when professional judgment concerning a primary interest (such as patients' welfare or the validity of research) may be influenced by a secondary interest (such as financial gain).”

All authors are required to disclose any financial relations, activities, relationships and affiliations that exist, or have existed, in the 36 months prior to submission with any commercial organizations, groups, institutions, or any other entities that has any interest in the subject matter, materials, or process(es) discussed in the manuscript. This includes, but is not limited to:

- Grant/research funding from a for-profit organization
- Consulting fee/honorarium
- Patent royalties/licensing fees

- Employment/leadership position/advisory role
- Others (travel fees, gift, etc.)

Any possible COI related to the study presented in the manuscript must be disclosed on the title page under the heading “Conflicts of Interest” using the following examples for each author:

“A (author name) received honoraria from Z (entity name); B holds an advisory role in Y;
C is an employee of Company X.”

If the manuscript is accepted for publication, the disclosures will be published as they appear in this section. If there are no COIs, the authors should state “The authors declare that there are no conflicts of interest” on the title page.

All sources of funding from entities such as government or non-profit organizations, which are relevant to the study, should be acknowledged on the title page under the heading “Sources of Funding.”

- You must use the following word format to describe any funding: “This work was supported by [*name of funder*] grant number [xxx]”.
- If your work did not receive funding you must use the following wording: “This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors”.
- You must ensure that the full, correct, details of your funder(s) and any relevant grant numbers are included.

9.8 Research Ethics

- A) Clinical research included in articles that report on human subjects or materials of human origin, must comply with the provisions of the Declaration of Helsinki. In addition, the “Materials and Methods” section must include a statement that the research was approved by the IRB of the authors’ affiliated institutions and the approval code issued by the IRB and the name of the institution, which granted the approval. Those researchers who do not have access to an ethics review committees should follow the principles outlined in the [Declaration of Helsinki](#).
- B) Articles reporting on data from animal testing must indicate in the “Materials and Methods” section the approval of the testing design by the affiliated institution’s Animal Care and Use Committee. Also, manuscripts describing animal experiments should be conducted in accordance with the experimental animal guidelines of the institution as well as the appropriate guidelines, such as those published by the Japanese Ministry of Education, Culture, Sports, Science and Technology and [Public Health Service Policy on Humane Care and Use of Laboratory Animals](#).
- C) Authors of articles reporting on new DNA sequences must furnish that data to the GenBank and include the accession number for it in the article.
- D) For any studies involving human subjects it should be stated clearly in the text that written consent has been obtained from all patients (or parent or legal guardian) to publish the information, including their photographs.
- E) Any data or information such as patient names, initials, hospital patient identification codes (patient IDs), specific dates, or any other information which may identify patients must not be presented anywhere in the manuscript, including the Figures and Tables unless the information is essential for scientific purposes and the patient (or parent or legal guardian). All pictures should focus on the affected areas only.

9.9 Misconduct and Breach of Publication Ethics

- All members of the Editorial Board of AATEX promote and abide by the [COPE International Standards for responsible research publication for authors, reviewers and editors](#) when dealing with allegations of misconduct. Please see our Ethical Polices for the information.
- All manuscripts submitted to AATEX must represent the authors’ original work and not duplicate any other previously published work in any language. The authors must understand, and guarantee, that the same manuscript is not simultaneously submitted to, or not under consideration in, another journal.
- All authors are fully responsible for the originality and contents of their submitted manuscripts. All records and data presented in the manuscript must be accurate, without any fabrication, manipulation, or falsification.
- Authors certify that the single research or dataset is not intentionally divided into several parts to increase the number of submission or publication with AATEX or other journals over time (“salami publication”).
- All information and contents, such as data, text, ideas, or theories that originate from other resources must be credited and cited, as guided in the “References” of Manuscript Preparation section.
- Any misconduct that is identified is subject to investigation by the Editorial Board according to the guidelines recommended by [COPE](#). If the allegation raises any valid concerns after the investigation, the author will be contacted to address the issue. The Editor-in-Chief may decide to publish an “Expression of Concern” if suspicion is raised after the article has already been published. Should misconduct or the breach of publication ethics be established, regardless of the level or seriousness, this may result in retraction,

publication of formal notice of the misconduct, formal notice to the author's institution, and a formal embargo on future contribution to AATEX.

10. Proofing and Revision after Acceptance

Authors of accepted manuscripts will be asked to submit the final version of the paper on diskettes, including text, tables and figures, to the Editorial Office. Information on file formats will be sent to authors with the letter of acceptance. Galley proofs will be available to the authors for corrections of minor errors such as spelling errors and omitted characters or letters. Any other corrections and revisions after the acceptance of a manuscript are not permitted unless requested by the Editorial Board of AATEX. Authors are expected to perform the proofing, as instructed by the Editorial Office. Upon completion of the proofing, authors should immediately email the revised proof to the Editorial Office.

After publication, further changes, or corrections, can only be made in the form of an Erratum which will be hyperlinked to the original article.

11. Copyright

Copyright of articles and their contents published in AATEX belong to the Japanese Society for Alternatives to Animal Experimentations. AATEX is an open access journal distributed under the Creative Commons Attribution-NoDerivatives 4.0 International License (<https://creativecommons.org/licenses/by-nd/4.0/>). Anyone may download, reuse, copy, reprint, or distribute articles published in the journal if they cite the original authors and source properly. If you remix, transform, or build upon the material, you may not distribute the modified material.

12. Charges

AATEX is fully funded by Japanese Society for Alternatives to Animal Experimentations. There is no charge to submit to or publish a manuscript in the journal.

13. Advertisement Policy

AATEX does not accept advertising from pharmaceutical companies, device manufacturers or any other commercial entities to avoid potential conflicts of interest in editorial decision-making and to avoid advertisements by companies with potentially competing interests appearing alongside articles published in the journal.

For inquiries:

Alternatives to Animal Testing and EXperimentation Editorial Office

E-mail: komizu@bio.sojo-u.ac.jp